A new study has proposed a mechanism for the pathogenesis of cerebral cavernous malformation (CCM) that links endothelial CCM3 deficiency to increased secretion of the vascular destabilizing protein angiopoietin-2 (ANGPT2).
References
Clatterbuck, R.E., Eberhart, C.G., Crain, B.J. & Rigamonti, D. J. Neurol. Neurosurg. Psychiatry 71, 188–192 (2001).
Plummer, N.W., Zawistowski, J.S. & Marchuk, D.A. Curr. Neurol. Neurosci. Rep. 5, 391–396 (2005).
Draheim, K.M., Fisher, O.S., Boggon, T.J. & Calderwood, D.A. J. Cell Sci. 127, 701–707 (2014).
Chan, A.C. et al. J. Clin. Invest. 121, 1871–1881 (2011).
Whitehead, K.J. et al. Nat. Med. 15, 177–184 (2009).
Zhou, Z. et al. Nature 532, 122–126 (2016).
Maddaluno, L. et al. Nature 498, 492–496 (2013).
Zhou, H.J. et al. Nat. Med. 22, 1033–1042 (2016).
Fiedler, U. et al. Blood 103, 4150–4156 (2004).
Gibson, C.C. et al. Circulation 131, 289–299 (2015).
Hapani, S., Chu, D. & Wu, S. Lancet Oncol. 10, 559–568 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D.Y.L. is cofounder of the biotechnology companies Navigen and Recursion Pharmaceuticals.
Rights and permissions
About this article
Cite this article
Zhao, H., Mleynek, T. & Li, D. Dysregulated exocytosis of angiopoietin-2 drives cerebral cavernous malformation. Nat Med 22, 971–973 (2016). https://doi.org/10.1038/nm.4178
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.4178
- Springer Nature America, Inc.